CVM net incomeQ3 2026-$5.67M
CVM net income was -$5.67M in fiscal Q3 2026 (ended Jun 30, 2026), compared with -$5.66M a year earlier. For the full fiscal 2025 it was -$25.41M, compared with -$26.92M in fiscal 2024.
Cel-Sci Corporation (CVM) financials
For the twelve months ended Jun 30, 2026, Cel-Sci Corporation reported -$22.70M of net income.
- Net income, TTM
- -$22.70M
- Free cash flow, TTM
- -$16.75M
- Cash
- $6.53M
- Market cap
- $25.5M
FY2016FY2025
FY2016FY2025
CVM revenue and earnings growth
CVM EPSQ3 2026-$0.47
CVM diluted EPS was -$0.47 in fiscal Q3 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$6.27.
CVM free cash flowQ3 2026-$4.03M
CVM free cash flow was -$4.03M in fiscal Q3 2026 (ended Jun 30, 2026), compared with -$3.94M a year earlier. For the full fiscal 2025 it was -$17.16M, compared with -$18.91M in fiscal 2024.
Income statement
| Line item | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | Sep 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $15.89M | $18.16M | $22.47M | $25.36M | $23.11M | $17.84M | $12.66M | $10.91M | $15.61M | $17.45M |
| Selling, general and admin | $8.92M | $8.19M | $9.00M | $10.71M | $13.09M | $11.70M | $8.00M | $6.33M | $5.80M | $6.49M |
| Operating income | -$24.81M | -$26.35M | -$31.48M | -$36.06M | -$36.19M | -$28.99M | -$20.20M | -$16.77M | -$21.41M | -$23.65M |
| Interest expense | $649.0K | $746.0K | $675.4K | $1.08M | - | $1.20M | - | - | - | - |
| Pre-tax income | - | - | - | - | - | -$30.26M | -$22.13M | - | - | - |
| Net income | -$25.41M | -$26.92M | -$32.37M | -$36.70M | -$36.36M | -$30.26M | -$22.13M | -$31.84M | -$14.36M | -$11.51M |
| EPS, basic | - | - | - | -$26.10 | -$27.00 | -$24.60 | -$21.30 | -$56.10 | -$54.90 | -$71.10 |
| EPS, diluted | -$6.27 | -$15.31 | -$21.90 | -$26.10 | -$27.00 | -$24.60 | -$21.30 | -$56.10 | -$57.30 | -$71.10 |
| Diluted shares | 4.1M | 1.8M | 1.5M | 1.4M | 1.4M | 1.2M | 1.0M | 566,824.067 | 263,421.567 | 162,206.8 |
Balance sheet
| Line item | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | Sep 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $10.95M | $4.74M | $4.15M | $22.67M | $36.06M | $15.51M | $8.44M | $10.31M | $2.37M | $2.92M |
| Short-term investments | - | - | - | $0 | $6.15M | $0 | - | - | - | - |
| Receivables | - | - | - | $0 | $54.9K | $54.9K | $62.8K | $118.7K | $218.5K | $394.5K |
| Inventory | - | $1.02M | $2.25M | $2.00M | $2.01M | $820.1K | $782.4K | $645.2K | $672.5K | $1.01M |
| Current assets | $11.60M | $6.06M | $6.92M | $25.44M | $45.27M | $17.70M | $9.81M | $11.44M | $4.24M | $5.46M |
| Total assets | $28.16M | $26.99M | $30.53M | $50.52M | $75.87M | $40.54M | $27.62M | $29.59M | $22.92M | $24.89M |
| Current liabilities | $5.13M | $4.62M | $5.59M | $4.66M | $3.94M | $4.27M | $3.02M | $9.23M | $10.84M | $4.01M |
| Long-term debt | $5.68M | - | - | - | - | - | - | - | - | - |
| Total debt | $5.68M | - | - | - | - | - | - | - | - | - |
| Total liabilities | $12.20M | $14.12M | $17.31M | $18.36M | $19.34M | $20.81M | $22.49M | $29.59M | $26.26M | $25.57M |
| Shareholders' equity | $15.96M | $12.87M | $13.21M | $32.16M | $56.53M | $19.73M | $5.13M | $916 | -$3.34M | -$679.2K |
Cash flow
| Line item | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | Sep 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$17.12M | -$18.81M | -$22.85M | -$18.24M | -$18.79M | -$15.28M | -$16.32M | -$13.39M | -$13.79M | -$23.08M |
| Capital expenditures | $38.1K | $94.9K | $361.9K | $637.9K | $9.02M | $2.65M | -$177.8K | $1.0K | $10.5K | $31.4K |
| Free cash flow | -$17.16M | -$18.91M | -$23.21M | -$18.88M | -$27.80M | -$17.93M | -$16.50M | -$13.39M | -$13.80M | -$23.11M |
| Investing cash flow | -$38.1K | -$108.1K | -$372.3K | $5.49M | -$15.18M | -$2.69M | -$335.8K | -$58.1K | -$17.0K | -$34.2K |
| Financing cash flow | $23.37M | $19.51M | $4.69M | -$638.4K | $54.52M | $25.04M | $14.79M | $21.39M | $13.26M | $20.31M |
| Stock-based compensation | $1.91M | $4.27M | $6.29M | $11.39M | $13.69M | $10.11M | $4.43M | $2.74M | $1.38M | $2.11M |
| Depreciation and amortization | $2.06M | $2.13M | $2.11M | $1.98M | $447.0K | $389.0K | $588.0K | $575.0K | $593.0K | $626.0K |
Key ratios
| Line item | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | Sep 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on equity | -159.2% | -209.2% | -244.9% | -114.1% | -64.3% | -153.4% | -431.2% | -3475677.4% | - | - |
| Return on assets | -90.3% | -99.7% | -106.0% | -72.6% | -47.9% | -74.6% | -80.1% | -107.6% | -62.7% | -46.3% |
| Current ratio | 2.26 | 1.31 | 1.24 | 5.45 | 11.50 | 4.15 | 3.25 | 1.24 | 0.39 | 1.36 |
| Debt to equity | 0.36 | - | - | - | - | - | - | - | - | - |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $3.65M | $3.77M | $3.68M | $3.70M | $3.74M | $4.01M | $4.43M | $4.48M | $4.70M | $4.63M | $4.35M | $5.27M |
| Selling, general and admin | $1.91M | $1.56M | $1.69M | $2.33M | $1.75M | $2.38M | $2.46M | $1.64M | $1.97M | $2.45M | $2.13M | $2.20M |
| Operating income | -$5.56M | -$5.33M | -$5.37M | -$6.03M | -$5.49M | -$6.39M | -$6.89M | -$6.12M | -$6.67M | -$7.08M | -$6.49M | -$7.47M |
| Interest expense | $111.0K | $117.0K | $88.0K | $129.0K | $172.0K | $178.0K | $170.0K | - | - | - | - | - |
| Net income | -$5.67M | -$5.47M | -$5.47M | -$6.10M | -$5.66M | -$6.57M | -$7.07M | -$6.11M | -$6.86M | -$7.24M | -$6.71M | -$7.80M |
| EPS, diluted | -$0.47 | -$0.67 | -$0.68 | - | -$1.36 | -$2.33 | -$3.25 | - | -$125.40 | -$4.20 | -$4.20 | - |
| Diluted shares | 12.1M | 8.1M | 8.0M | - | 4.2M | 2.8M | 2.2M | - | 59,993.767 | 1.7M | 1.6M | - |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $6.53M | $1.89M | $6.28M | $10.95M | $1.79M | $1.92M | $4.61M | $4.74M | $384.7K | $5.31M | $3.24M | $4.15M |
| Inventory | - | - | - | - | - | - | - | $1.02M | - | - | $2.35M | $2.25M |
| Current assets | $7.50M | $2.89M | $7.03M | $11.60M | $2.62M | $3.02M | $5.86M | $6.06M | $3.54M | $8.51M | $6.15M | $6.92M |
| Total assets | $21.36M | $17.71M | $22.89M | $28.16M | $20.34M | $21.81M | $25.70M | $26.99M | $24.07M | $30.05M | $28.71M | $30.53M |
| Current liabilities | $5.08M | $4.81M | $5.04M | $5.13M | $5.62M | $5.50M | $5.48M | $4.62M | $5.51M | $5.09M | $4.87M | $5.59M |
| Long-term debt | - | - | - | $5.68M | - | - | - | - | - | - | - | - |
| Total debt | - | - | - | $5.68M | - | - | - | - | - | - | - | - |
| Total liabilities | $10.40M | $10.83M | $11.76M | $12.20M | $13.31M | $13.81M | $14.39M | $14.12M | $15.60M | $15.74M | $16.06M | $17.31M |
| Shareholders' equity | $10.96M | $6.87M | $11.14M | $15.96M | $7.02M | $8.00M | $11.31M | $12.87M | $8.47M | $14.30M | $12.65M | $13.21M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.03M | -$4.02M | -$4.02M | -$4.67M | -$3.94M | -$4.37M | -$4.14M | -$4.82M | -$4.58M | -$4.53M | -$4.89M | -$5.04M |
| Capital expenditures | $0 | $0 | $0 | $5.2K | $0 | $0 | $33.0K | $19.8K | $23.5K | $0 | $51.6K | $0 |
| Free cash flow | -$4.03M | -$4.02M | -$4.02M | -$4.68M | -$3.94M | -$4.37M | -$4.17M | -$4.84M | -$4.60M | -$4.53M | -$4.94M | -$5.04M |
| Investing cash flow | $0 | $0 | $0 | -$5.2K | $0 | $0 | -$33.0K | -$19.8K | -$23.5K | $0 | -$64.9K | -$10.4K |
| Financing cash flow | $8.67M | -$364.5K | -$653.8K | $13.84M | $3.81M | $1.68M | $4.05M | $9.19M | -$322.3K | $6.60M | $4.05M | $4.07M |
| Stock-based compensation | $454.1K | $451.4K | $443.3K | $440.5K | $73.4K | $685.7K | $711.4K | $725.6K | $728.1K | $1.43M | $1.38M | $1.31M |
| Depreciation and amortization | $946.4K | $956.4K | $964.4K | -$868.3K | $959.0K | $970.1K | $995.2K | -$842.6K | $984.2K | $988.8K | $1.00M | -$845.7K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 1.48 | 0.60 | 1.39 | 2.26 | 0.47 | 0.55 | 1.07 | 1.31 | 0.64 | 1.67 | 1.26 | 1.24 |
| Debt to equity | - | - | - | 0.36 | - | - | - | - | - | - | - | - |
Source: XBRL data Cel-Sci Corporation files with the SEC, latest filing dated Aug 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-10, first reported Dec 27, 2013; 1-for-25, first reported Aug 9, 2017; 1-for-30, first reported Dec 29, 2025.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
CVM peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| CVM | - | - | -$22.70M | - | $25.5M |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $249.05B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $207.00B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $101.48B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $57.55B |
| RVMD | $0 | - | -$1.13B | - | $41.59B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $36.71B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.98B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $16.98B |
CVM FAQ
5 questionsIs CVM profitable?
No. Cel-Sci Corporation reported a net loss of $22.70M for the twelve months ended Jun 30, 2026.How much cash and debt does CVM have?
Cel-Sci Corporation reported $6.53M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is CVM free cash flow?
Cel-Sci Corporation generated -$16.75M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$16.75M less capital expenditures.When did CVM last report financial results?
The latest statements here come from Cel-Sci Corporation's 10-Q filed on Aug 14, 2026, covering the period ended Jun 30, 2026.Where does this CVM financial data come from?
Quantisnow builds these statements from the structured XBRL data Cel-Sci Corporation files with the SEC. It is provided for information only and is not investment advice.